Medibank Private Ltd (ASX: MPL) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Medibank Private Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $9.75 billion
P/E Ratio 22.27
Dividend Yield 3.57%
Shares Outstanding 2.75 billion
Earnings per share 0.131
Dividend per share 0.14
Year To Date Return 22.49%
Earnings Yield 4.49%
Franking 100%
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Medibank Private Ltd (ASX: MPL)
Latest News

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
08 Sep 2021 $0.0690 100.00% Final 30 Sep 2021
03 Mar 2021 $0.0580 100.00% Interim 25 Mar 2021
02 Sep 2020 $0.0630 100.00% Final 24 Sep 2020
03 Mar 2020 $0.0570 100.00% Interim 26 Mar 2020
04 Sep 2019 $0.0250 100.00% 26 Sep 2019
04 Sep 2019 $0.0740 100.00% Final 26 Sep 2019
05 Mar 2019 $0.0570 100.00% Interim 28 Mar 2019
05 Sep 2018 $0.0720 100.00% Final 27 Sep 2018
06 Mar 2018 $0.0550 100.00% Interim 28 Mar 2018
06 Sep 2017 $0.0675 100.00% Final 28 Sep 2017
07 Mar 2017 $0.0525 100.00% Interim 29 Mar 2017
06 Sep 2016 $0.0600 100.00% Final 28 Sep 2016
04 Mar 2016 $0.0500 100.00% Interim 29 Mar 2016
03 Sep 2015 $0.0530 100.00% 28 Sep 2015

MPL ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Medibank Private Ltd

Medibank Private Ltd (ASX: MPL) is an integrated healthcare company providing private health insurance and health solutions to 3.7 million Australians. Medibank’s core business is the underwriting and distribution of private health insurance policies – as well as travel, life and pet insurances – through its two brands, Medibank and AHM.

Medibank offers hospital cover and extras cover to customers in Australia as well as health insurance to overseas visitors and students. It also provides integrated healthcare services to policyholders, government, corporate and other customers. These include mental health support, preventative and better integrated primary care and after-hours health support.

Established as a not-for-profit private health insurer by the Australian government in 1976, Medibank was sold and listed on ASX in 2014. The Medibank share price peaked at $3.67 in July 2019.

MPL Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
17 Sep 2021 $3.54 $-0.02 -0.56% 10,750,582 $3.56 $3.57 $3.52
16 Sep 2021 $3.56 $0.03 0.85% 7,422,162 $3.54 $3.57 $3.51
15 Sep 2021 $3.53 $-0.02 -0.56% 5,988,894 $3.58 $3.58 $3.51
14 Sep 2021 $3.55 $-0.02 -0.56% 12,384,063 $3.58 $3.58 $3.52
13 Sep 2021 $3.57 $0.00 0.00% 7,086,451 $3.55 $3.58 $3.54
10 Sep 2021 $3.57 $0.05 1.42% 9,782,493 $3.60 $3.61 $3.53
09 Sep 2021 $3.52 $0.00 0.00% 11,535,116 $3.51 $3.53 $3.49
08 Sep 2021 $3.52 $-0.10 -2.76% 12,972,571 $3.53 $3.61 $3.51
07 Sep 2021 $3.62 $0.02 0.56% 5,680,687 $3.59 $3.62 $3.58
06 Sep 2021 $3.60 $0.03 0.84% 4,421,300 $3.53 $3.60 $3.53
03 Sep 2021 $3.57 $0.01 0.28% 4,610,379 $3.56 $3.58 $3.53
02 Sep 2021 $3.56 $-0.01 -0.28% 7,599,751 $3.58 $3.60 $3.51
01 Sep 2021 $3.57 $0.02 0.56% 4,151,157 $3.51 $3.57 $3.50
31 Aug 2021 $3.55 $0.00 0.00% 7,993,681 $3.51 $3.55 $3.50
30 Aug 2021 $3.55 $0.02 0.57% 3,898,120 $3.53 $3.55 $3.49
27 Aug 2021 $3.53 $-0.02 -0.56% 7,574,326 $3.51 $3.55 $3.48
26 Aug 2021 $3.55 $0.00 0.00% 10,337,765 $3.53 $3.55 $3.48
25 Aug 2021 $3.55 $0.02 0.57% 6,095,111 $3.60 $3.60 $3.49
24 Aug 2021 $3.53 $-0.06 -1.67% 9,847,083 $3.57 $3.60 $3.53
23 Aug 2021 $3.59 $-0.01 -0.28% 12,806,695 $3.59 $3.60 $3.51
20 Aug 2021 $3.60 $0.02 0.56% 8,299,138 $3.58 $3.62 $3.57
19 Aug 2021 $3.58 $0.04 1.13% 6,216,034 $3.53 $3.59 $3.53

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
27 Aug 2021 David Koczkar Exercise 65 $229,608
Conversion of securities. 525,187 - Performance Rights
27 Aug 2021 David Koczkar Buy 65 $229,608
Conversion of securities.
27 Aug 2021 David Koczkar Expiry 138 $487,913
As advised by the company. 386,968 - Performance Rights
138,219 lapsed Performance Rights
26 Nov 2020 Craig Drummond Issued 761 $2,217,187
Issue of securities. 2,217,668 - Performance Rights.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Michael (Mike) John Wilkins Non-Executive DirectorNon-Executive Chairman May 2017
Mr Wilkins has more than 20 years of experience as CEO for ASX100 companies. Mr Wilkins is the Chairman (since March 2020) and a director (since November 2016) of QBE Insurance Group Limited. He is also a director of Scentre Group Limited (since April 2020). Mike has more than 30 years of experience in financial services, predominantly in Australia and Asia. He served as Managing Director and Chief Executive Officer at Insurance Australia Group (November 2007 to November 2015), Managing Director and Chief Executive Officer at Promina Group Limited and Managing Director at Tyndall Australia Limited. He also served as Acting Chief Executive Officer (April 2018 to December 2018), Executive Chairman (April 2018 to June 2018) and a director (September 2016 - February 2020) of AMP Limited. He was previously a director of Maple-Brown Abbott Limited, Alinta Limited, The Geneva Association and the Australian Business and Community Network. He is a member of the Risk Management Committee and the Investment and Capital Committee of Medibank.
Mrs Linda Bardo Nicholls Non-Executive Director Mar 2014
Mrs Nicholls has more than 30 years of experience as a senior executive and director in banking, insurance and funds management in Australia, New Zealand and the United States. She was previously Chairman (October 2008 to October 2010) and a director (January 2000 to October 2010) of Healthscope, Chairman of KDR Victoria Pty Ltd (Yarra Trams) (2009 to 2016) and a director of Pacific Brands Limited (October 2013 to July 2016), Sigma Pharmaceuticals Limited (December 2005 to December 2015) and Fairfax Media Limited (February 2010 to December 2018). She is currently Chairman of Japara Healthcare Limited (since March 2014) and a director of Inghams Group Limited (since November 2016). Linda is also Chairman of the Board of Melbourne Health and a member of the Museum's Board of Victoria. She is Chairman of the People Committee.
Ms Christine Elizabeth O'Reilly Non-Executive Director Mar 2014
Ms O'Reily has more than 30 years of financial and infrastructure experience both in Australia and internationally in various roles including as Co-head of Unlisted Infrastructure at Colonial First State Global Asset Management and Chief Executive and Managing Director of GasNet Australia Group. Christine is currently a director of CSL Limited (since February 2011), Transurban Group (since April 2012), Stockland (since August 2018) and The Baker Institute. She is member of the Risk Management Committee.
Mr Peter Hodgett Non-Executive Director Jun 2013
Mr Hodgett worked for AMP for more than 20 years in a wide variety of business and functional roles, including Chief Actuary during its demutualisation, General Manager of Human Resources and Strategy, and as Global Director of Finance and Operations for Henderson Global Investors in the United Kingdom. He was also a director (until June 2019) of Colonial First State Investments Limited, Colonial Mutual Superannuation Pty Limited and Avanteos Investments Limited. He is Chairman of the Investment and Capital Committee.
Mr David Fagan Non-Executive Director Mar 2014
Mr Fagan is experienced banking and major projects lawyer with more than 39 years of experience. He acted for major banks and corporate clients with Clayton Utz, and was Clayton Utz's Chief Executive Partner from May 2001 to June 2010. David also chaired the Medibank Privatisation Committee which operated during 2014 in preparation for the privatisation process. David is a former director and Chair of the Audit Committee of the Global Foundation, a former director of Grocon Funds Management Group and the Hilco Group and a former member of the advisory board of Chase Corporate Advisory. David is currently a director of PayGroup Limited (since November 2017). He is a director and Chair of the Audit and Risk Committee of UBS Grocon Real Estate Investment Management Pty Ltd and a member of the ASIC Director Advisory Panel. He is Chairman of the Risk Management Committee and a member of the Investment and Capital Committee.
Ms Anna Bligh Non-Executive Director Dec 2014
Ms Bligh has experience in leadership and public policy, including in the fields of healthcare, finance, infrastructure and project management. She has held several roles in the Queensland Government, including Premier, Treasurer, Minister for Finance, Minister for State Development, Minister for Trade and Innovation and Minister for Education. She was also a member of the Queensland Cabinet Budget Review Committee for 11 years. Anna is currently the Chief Executive Officer of the Australian Banking Association and a director of Bangarra Dance Theatre Australia. She is a member of the Investment and Capital Committee and the People Committee.
Mr David Koczkar Chief Executive OfficerManaging Director May 2021
Mr Koczkar has more than 25 years of leadership experience in customer focused businesses, including previous work in strategy consulting and finance industries. Prior to that he held the role of Chief Operating Officer from March 2014 and was Acting Chief Executive Officer between April 2016 and June 2016. As Chief Customer Officer David has been responsible for Medibank Group's consumer businesses, including the health and diversified insurance portfolios, Live Better and the ahm business. Prior to joining Medibank, David was the Group Chief Commercial Officer at Jetstar where he was responsible for the airline's customer and commercial businesses across the Asia Pacific region.
Dr Tracey Batten Non-Executive Director Aug 2017
Dr Bratten has experience in the health services sector, with strong commercial, business and change leadership skills. Most recently, Tracey was the Chief Executive of the Imperial College Healthcare NHS Trust in the United Kingdom. In that role, Tracey focused on change leadership, in particular improving organisational culture and strengthening patient safety and experience. Tracey also oversaw the implementation of a range of digital initiatives as Chief Executive. Tracey is a former Chief Executive of St Vincent's Health Australia. Tracey is currently a director of Abano Healthcare Group Limited, the National Institute of Water and Atmospheric Research in New Zealand and the New Zealand Accident Compensation Corporation. She is a member of the Risk Management Committee and the People Committee.
Mr Gerard Dalbosco Non-Executive Director May 2021
Mr Dalbosco was a Partner of EY until September 2020, where he held a number of senior leadership roles, including Asia Pacific Managing Partner - Markets and Co-Deputy CEO where he led EY's clientserving activities across the Asia-Pacific market; Oceania Managing Partner and CEO where he was responsible for EY's Oceania business, Oceania Managing Partner of Transaction Advisory Services where he was responsible for EY's Transaction Advisory Services business across Oceania, and most recently Melbourne Managing Partner, where he led a team of Partners and staff and was responsible for EY's go-to-market and client service strategies, as well as its involvement in the broader Melbourne community. Mr Dalbosco has previously held roles as Director and Chair of the Finance & Audit Committee of Mercy Health & Aged Care, Director and member of the Finance Committee of Berry Street Victoria, Co-Deputy Chair and Chair of the Finance Committee of the Committee for Melbourne and Chair of the National Gallery of Victoria's Business Council. Mr Dalbosco will also join the Risk Management Committee of MPL.
Ms Mei Ramsay Group General CounselCompany Secretary Mar 2011
Mei Ramsay Group General CounselCompany Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Hsbc Custody Nominees (Australia) Limited 843,775,076 30.64%
J P Morgan Nominees Australia Pty Limited 565,553,382 20.54%
Citicorp Nominees Pty Limited 231,986,783 8.42%
National Nominees Limited 150,880,935 5.48%
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 70,767,066 2.57%
BNP Paribas Noms Pty Ltd <Drp> 41,621,581 1.51%
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 27,939,044 1.01%
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 11,436,005 0.42%
Navigator Australia Ltd <Sma Antares Inv Dv Build A/C> 6,858,618 0.25%
Australian Executor Trustees Limited <Ips Super A/C> 6,739,696 0.24%
The Senior Master Of The Supreme Court <Common Fund No 3 A/C> 6,500,000 0.24%
Ubs Nominees Pty Ltd 6,419,250 0.23%
HSBC Custody Nominees (Australia) Limited Gsco Eca 4,428,496 0.16%
AMP Life Limited 4,420,770 0.16%
Netwealth Investments Limited <Wrap Services A/C> 3,875,287 0.14%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 3,659,226 0.13%
Hsbc Custody Nominees (Australia) Limited I 2,973,110 0.11%
Netwealth Investments Limited <Super Services A/C> 2,252,577 0.08%
National Nominees Limited <Db A/C> 2,231,402 0.08%
BNP Paribas Noms (Nz) Ltd <Drp> 2,176,759 0.08%